Venclyxto Gets EU Nod – But Won't Be A Humira Replacement For AbbVie Yet

AbbVie and Genentech's chronic lymphocytic leukemia (CLL) drug Venclyxto has been recommended for conditional approval in Europe, but its initial limited patient population and potential reimbursement troubles won't see it replace top-seller Humira as a growth driver for AbbVie.

SC1610_Blurred-Pharmacy-Store_1200x675
AbbVie will need to pursue label extensions for Venclyxto in CLL • Source: Shutterstock

The EMA's scientific advisory body, the committee for medicinal products for human use (CHMP), has given AbbVie and Genentech (a Roche company) the green light for conditional approval of their jointly developed chronic lymphocytic leukemia (CLL) product, Venclyxto (venetoclax). But both companies will need to carefully position the drug alongside their existing CLL therapies – AbbVie's Imbruvica (ibrutinib) and Roche's Gazyva – to avoid cannibalization of sales.

Furthermore, AbbVie will need to pursue label extensions quickly in CLL if Venclyxto is going to help prevent pending profit...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip